PDCD1 and hepatitis B virus infection: It suggested that PD-1 inhibitors combined with NAs may have therapeutic effects on chronic HBV infection, and may contribute to the clinical cure of hepatitis B. However, due to the influence of the PD-1 inhibitor itself or other combined antineoplastic therapies, the state of HBsAg loss in some patients cannot be stably maintained.